Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leukocyte-specific transcript 1 protein is a membrane-bound transmembrane adaptor protein, predominantly expressed in leukocytes of the myeloid lineage, where it localizes to tetraspanin-enriched microdomains. It lacks enzymatic activity but contains conserved phosphotyrosine-based motifs (ITIM and ITIM-like) that allow it to interact with SHP-1 and SHP-2 phosphatases, thereby contributing to the negative regulation of immunological signaling. LST1 modulates immune responses and can inhibit lymphocyte proliferation. It can also induce morphological changes such as filopodia formation and may play a role in dendritic cell maturation. While associated with alternative splicing and multiple isoforms, only the LST1/A isoform is clearly conserved and detected in vivo. Genetic variation in LST1 has been linked with isolated cleft palate but lacks well-characterized associations with major common diseases[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leukocyte-specific transcript 1 protein (LST1).